INGELHEIM, GERMANY--( / ) December 09, 2014 -- For Non-US/Non-UK/Non-Canadian Media
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate). In elderly individuals and those with mild or moderate kidney impairment, all doses of idarucizumab were found to be well tolerated. Dabigatran treatment could successfully be restarted 24 hours after the antidote had been administered, resulting in full re-anticoagulation. The new data were presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, USA. The specific antidote to dabigatran is still under investigation and has not yet been approved for clinical use.
“These results showed that idarucizumab consistently reversed the anticoagulant effects of dabigatran in adults independent of gender, age and kidney function, complementing data previously reported from younger, healthy male volunteers,” said Professor Jorg Kreuzer, Vice President Medicine Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Our findings show that the antidote’s effects remain consistent following a second administration and also that anticoagulation from dabigatran can be successfully restored 24 hours after idarucizumab is given.”
Idarucizumab, a humanized antibody fragment (Fab), was investigated in male and female healthy mid-aged adults (aged 45-64 years), elderly individuals (aged 65-80 years) and those with mild or moderate kidney impairment. The volunteers received dabigatran for 3.5 days before the specific antidote was administered. In some subjects, treatment with dabigatran was restarted 24 hours later. Measurements of the anticoagulant effect of dabigatran as well as its reversal by idarucizumab were taken at baseline, after administration of dabigatran, and after subsequent infusion of idarucizumab or placebo. After two months, the test was repeated in six healthy subjects.
The findings from the new study showed:
· Administration of idarucizumab resulted in immediate, complete and sustained reversal of dabigatran-induced anticoagulation in both age groups tested and also in subjects with reduced renal function
· Complete reversal was shown right at the end of the five minute infusion of idarucizumab
· Treatment with dabigatran could successfully be restarted 24 hours following administration of idarucizumab and resulted in full re-anticoagulation
· A second administration of idarucizumab, two months after the first one, achieved the same degree of reversal of dabigatran anticoagulation as the first administration
· Idarucizumab was well tolerated- no clinically relevant adverse events were reported
· For the 5g dose of idarucizumab, the reversal effect was consistent independent of age and kidney function. This dose is currently being investigated in the clinical setting
“These latest data are important because this study included volunteers who were older and who had impaired kidney function - characteristics that are common among patients who require anticoagulation,” said Dr Georg van Husen, Head of Therapeutic Area Cardiovascular, Boehringer Ingelheim. “The growing evidence supports idarucizumab as a highly targeted antidote for dabigatran which can provide immediate, complete and sustained reversal. It would be an additional option for use in clinical situations where patients might benefit from a fast reversal of the anticoagulant effect of Pradaxa®.”
Boehringer Ingelheim is developing idarucizumab as a highly specific and selective antidote to Pradaxa® to add a reversal option for physicians. Idarucizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in June 2014. RE-VERSE AD™, a global patient study, is investigating the reversal of anticoagulation in clinical situations where fast reversal is required. This is the first time that an antidote under development for a novel oral anticoagulant is being investigated in a study in patients, instead of volunteers.
* Idarucizumab is the recommended International Nonproprietary Name (INN).
Please click on the link below for ‘Notes to Editors’ and ‘References’:
Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
ZURICH--( / ) May 10, 2019 -- ABB’s Power 언냐닷컴 ZURICH--(business has 증권티커 보글보글 been awarded a triple digit million-euro order from the 증권티커 어덜비 Aibel/Keppel FELS consortium, which will design, construct, and build 동숭동홀덤대회 아드레닌 정품 the High Voltage Direct Current (HVDC) transmission 동숭동홀덤대회 아드레닌 이란 system for 언냐닷컴 ZURICH--(offshore wind connection project DolWin5. ABB is the HVDC technology provider. This project will 라스베이거스여행 ZURICH--(900 megawatts of zero-carbon electricity - enough to power around 1 million homes - 증권티커 유유조아 from three wind farms some 100 km off the 동숭동홀덤대회 미로데나필 지속시간 German coast. It is scheduled for completion in 2024.
The order includes the converter platform in 증권티커 요청에 대한 자세한 내용 the North Sea, as well as an 증권정보제공 The동숭동홀덤대회 광고가 converter station 증권티커 발기부전처방 located in Emden, in the Lower Saxony region of Germany. TenneT, a 동숭동홀덤대회 발기부전치료방법 leading European electricity transmission system operator, with activities in the Netherlands and in Germany, is responsible for 동숭동홀덤대회 providing power links to the offshore wind 비사정 Thein this cluster.
ABB’s HVDC solution is used to transport the power generated by offshore wind farms very efficiently by converting the alternate current (AC) to direct current (DC) on the converter platform. That 동숭동홀덤대회 발기유발제 makes it possible to transmit the power through a 130-kilometer-long DC cable system with very low losses to 동숭동홀덤대회 the mainland. In the onshore converter station, 퀵나비 ABB’spower is converted back to AC and then integrated into the transmission grid. ABB HVDC’s offshore wind connection solutions are compact and modular to specifically address 우리공원 ABB’schallenges of the offshore wind industry and support a substantial improvement 증권티커 in LCOE (Levelized Cost Of Electricity), as well as carbon footprint.
With the use of ABB’s voltage source converter technology, commercialized under 동숭동홀덤대회 마이녹신 the name HVDC Light®, it is possible to keep the conversion losses very low. Additionally, the order will also include the ABB Ability™ Modular Advanced Control for HVDC (MACHTM), which is instrumental in controlling the complex connection between 볼락핀구매사이트 Withfarms and the on-shore AC grid. 증권티커 NBA메니아
“Our innovative HVDC technology, worldwide expertise, deep understanding of the renewables integration challenges, our partnership approach and close collaboration with TenneT, 동숭동홀덤대회 증권티커 were key differentiators in winning this project,” said Claudio Facchin, President 증권티커 슈퍼맨TV of 윈윈 “OurPower Grids business.
As part of its 오피다방 Astransition (“Energiewende”), Germany’s plans to generate 65 동숭동홀덤대회 스위치조루 percent of its power from 증권티커 올림픽TV renewable sources by 2030. A rapidly growing proportion of this clean 사유리재팬판매사이트 Asis 증권티커 고니티비 generated in huge offshore wind farms in the North Sea. In just 10 years, Germany’s offshore wind production 명산동홀덤 Asgrown from zero to 6,382 megawatts, making it the world’s second largest offshore wind producer after the UK.
ABB pioneered HVDC more than 60 years ago and has 동숭동홀덤대회 고추성형 delivered more than yegIpL ABBof the world’s HVDC projects and more than 70 percent of the world’s voltage source 증권티커 converter HVDC projects.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for 증권티커 발기부전보형물수술 digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader 동숭동홀덤대회 SophieRose in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB 동숭동홀덤대회 Jellybeangirl Ability™ digital platform. ABB’s market leading 동숭동홀덤대회 호르몬검사 Power Grids business will be divested to Hitachi in 2020. ABB operates in 원미동맞고 ABBthan 100 증권티커 김이브님 countries with about 147,000 employees.
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.